Dec 22, 2021 9:00am EST Avalon GloboCare’s Chairman Converts Debt into Common Stock at 45% Premium to Market
Oct 14, 2021 9:20am EDT Avalon GloboCare Jointly Files US and International Patent Application for Breakthrough S-Layer Coated Emulsome Technology (SLET) for Next-Generation Drug Delivery and Cellular Immunotherapy
Oct 07, 2021 9:00am EDT Avalon GloboCare and University of Natural Resources and Life Sciences (BOKU) Co-develop Innovative In-Silico Technology, Enabling the Design and Synthesis of Novel Cell Membrane Receptor Targets for Cancer and Immune-Related Diseases
Sep 23, 2021 9:00am EDT Avalon GloboCare to Present at the Benzinga Healthcare Small Cap Conference on September 30th
Jul 01, 2021 9:00am EDT Avalon GloboCare Announces its Planned Acquisition Target, SenlangBio, has Initiated First-In-Human Clinical Trial in Recurrent Brain Cancer
Jun 28, 2021 9:04am EDT Avalon GloboCare CEO Provides Letter to Update Shareholders About Acquisition of SenlangBio
Jun 14, 2021 9:00am EDT Avalon GloboCare Announces Execution of Purchase Agreement for Acquisition of SenlangBio in All Stock Transaction
Jun 11, 2021 9:00am EDT Avalon GloboCare to Present at the Noble Capital Markets Investor Forum During the 16th Annual World Stem Cell Summit on June 17, 2021
Jun 08, 2021 9:00am EDT Avalon GloboCare To Present Its S-Layer and QTY Code Breakthrough Technology Platforms at The Prestigious Annual World Stem Cell Summit